ENDP up +1.27% percent Today $ENDP High is at 67.0
Post# of 109
Posted On: 11/17/2014 12:12:04 PM
ENDP up +1.27% percent Today $ENDP High is at 67.08 and the Low 66.13 with current volume of 119,992.
Recent News posted below.
Endo Pharmaceuticals Holdings Inc ENDP other info.
http://investorshangout.com/Endo-Health-Solut...NDP-54014/
ENDP Endo Pharmaceuticals Holdings Inc Recent Headline News
After Yesterday's Decline of 1.25%, Endo Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 4:38PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $66.00 to a high of $68.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $66.94 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 66.72 (+0.46)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 66.72 (+0.46), ACT: 249.80 (+6.03), JAZZ: 171.30 (-3.27), UNH: 96.09 (+0.98), CELG: 104.54 (+0.49), CELGZ: 3.28 (unch)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 66.72 (+0.46), LCI: 47.45 (+0.57), BCRX: 10.17 (+0.10), LJPC: 11.29 (+0.23)
Endo Receives Final Approval for Generic Version of Valcyte®
PR Newswire - Mon Nov 10, 7:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Qualitest subsidiary has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Hoffmann-La Roche, Inc.'s Valcyte® (Valganciclovir Tablets USP, 450 mg).
ENDP: 66.72 (+0.46), ENL.TO: 74.77 (-0.38)
Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST
ENDP: 66.72 (+0.46), AUXL: 32.24 (+0.07)
Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST
ENDP: 66.72 (+0.46), RDY: 55.94 (-0.09)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 210.46 (+11.81), ENDP: 66.71 (+0.45), AUXL: 32.24 (+0.07), ABBV: 65.29 (+1.29)
Endo International's (ENDP) CEO Rajiv Kanishka Liyanaarchchie De Silva on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:50PM CST
ENDP: 66.71 (+0.45)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.45 (+0.55), ENDP: 66.71 (+0.45), AUXL: 32.24 (+0.07), SHPG: 204.81 (+2.19), DNDN: 0.16 (+0.05), SNSS: 2.50 (+0.83), ABBV: 65.29 (+1.29), SNY: 47.39 (+0.71), MNKD: 6.14 (-0.02), XOMA: 3.97 (+0.05)
Endo International (ENDP) Is Today's Water-Logged And Getting Wetter Stock
at The Street - Wed Nov 05, 9:29AM CST
Trade-Ideas LLC identified Endo International (ENDP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ENDP: 66.71 (+0.45)
Endo updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:18AM CST
ENDP: 66.71 (+0.45)
Endo International (ENDP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:55AM CST
ENDP: 66.71 (+0.45)
Endo beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:09AM CST
ENDP: 66.71 (+0.45)
Endo Reports Third Quarter Financial Results
PR Newswire - Wed Nov 05, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported third quarter 2014 revenues of $764 million, an increase of 16 percent compared to third quarter 2013 revenues of $661 million. Endo reported a net loss of $252 million in the third quarter 2014 compared to net income of $40 million in the third quarter of 2013.
ENDP: 66.71 (+0.45), ENL.TO: 74.77 (-0.38)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST
MDLZ: 38.20 (+0.04), CSTE: 59.51 (+0.14), FSS: 15.67 (+0.02), HL: 2.46 (-0.06), BBEP: 15.12 (-0.43), RRD: 16.90 (-0.03), CNP: 24.16 (+0.12), INXN: 28.26 (-0.02), OGE: 36.53 (+0.18), MNTA: 10.63 (unch), GLDD: 7.05 (-0.18), AXAS: 3.89 (-0.18), MEMP: 16.13 (-0.24), PWE: 4.16 (-0.06), ROC: 79.15 (-0.04), SSYS: 104.67 (-0.18), DNR: 9.93 (-1.27), MVIS: 1.70 (unch), PWR: 33.09 (-0.07), COV: 94.39 (+0.41), SMG: 59.94 (-0.66), SEP: 56.90 (+0.54), CLH: 49.80 (+0.85), ATHM: 42.88 (-1.70), STWD: 23.46 (-0.06), BPI: 10.96 (-0.30), LVLT: 48.73 (-0.31), AVA: 33.70 (+0.24), MGA: 104.19 (+0.27), BSFT: 27.42 (-0.08), EE: 37.89 (+0.34), CTSH: 53.03 (-0.25), DAVE: 25.69 (-0.06), NRG: 31.22 (-0.09), CEQP: 8.37 (-0.09), ACT: 249.80 (+6.03), AWR: 34.52 (+0.28), DUK: 80.05 (+0.94), LAMR: 52.77 (+0.22), CCC: 21.06 (-0.16), HFC: 43.18 (+0.35), RTI: 23.45 (-0.17), CHK: 23.03 (-0.18), NUS: 39.26 (-0.14), NICE: 46.40 (-0.02), HRC: 45.04 (+0.28), ENDP: 66.71 (+0.45), SE: 38.44 (+0.32), CBB: 3.41 (-0.06), GTN: 10.20 (+0.09), ANSS: 79.94 (+0.15), RLGY: 42.73 (-0.24), ENB: 45.26 (-0.11), SBGI: 27.96 (-0.13), ARIA: 6.05 (-0.10), LPX: 14.61 (unch), RDC: 23.43 (-0.32), KELYA: 15.12 (-0.30)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 43.88 (+0.74), ENDP: 66.71 (+0.45), VRX: 134.94 (+0.73), PFE: 30.01 (-0.33)
Endo reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:03PM CDT
ENDP: 66.71 (+0.45)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.71 (+0.45), VRX: 134.94 (+0.73), ACT: 249.80 (+6.03), AMGN: 158.68 (+1.00), TKMR: 17.09 (+0.68), GSK: 45.84 (+0.10), AGN: 210.48 (+11.83), JNJ: 108.31 (+0.15), SHPG: 204.81 (+2.19), MRK: 59.62 (+0.55), INFI: 14.25 (+0.15), ABBV: 65.29 (+1.29), KPTI: 40.49 (+0.72)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 66.71 (+0.45), PRGO: 154.09 (-0.37), AUXL: 32.24 (+0.07), DEPO: 15.23 (+0.23), AMPE: 3.32 (-0.02)
Recent News posted below.
Endo Pharmaceuticals Holdings Inc ENDP other info.
http://investorshangout.com/Endo-Health-Solut...NDP-54014/
ENDP Endo Pharmaceuticals Holdings Inc Recent Headline News
After Yesterday's Decline of 1.25%, Endo Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 4:38PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $66.00 to a high of $68.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $66.94 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 66.72 (+0.46)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 66.72 (+0.46), ACT: 249.80 (+6.03), JAZZ: 171.30 (-3.27), UNH: 96.09 (+0.98), CELG: 104.54 (+0.49), CELGZ: 3.28 (unch)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 66.72 (+0.46), LCI: 47.45 (+0.57), BCRX: 10.17 (+0.10), LJPC: 11.29 (+0.23)
Endo Receives Final Approval for Generic Version of Valcyte®
PR Newswire - Mon Nov 10, 7:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Qualitest subsidiary has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Hoffmann-La Roche, Inc.'s Valcyte® (Valganciclovir Tablets USP, 450 mg).
ENDP: 66.72 (+0.46), ENL.TO: 74.77 (-0.38)
Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST
ENDP: 66.72 (+0.46), AUXL: 32.24 (+0.07)
Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST
ENDP: 66.72 (+0.46), RDY: 55.94 (-0.09)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 210.46 (+11.81), ENDP: 66.71 (+0.45), AUXL: 32.24 (+0.07), ABBV: 65.29 (+1.29)
Endo International's (ENDP) CEO Rajiv Kanishka Liyanaarchchie De Silva on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:50PM CST
ENDP: 66.71 (+0.45)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.45 (+0.55), ENDP: 66.71 (+0.45), AUXL: 32.24 (+0.07), SHPG: 204.81 (+2.19), DNDN: 0.16 (+0.05), SNSS: 2.50 (+0.83), ABBV: 65.29 (+1.29), SNY: 47.39 (+0.71), MNKD: 6.14 (-0.02), XOMA: 3.97 (+0.05)
Endo International (ENDP) Is Today's Water-Logged And Getting Wetter Stock
at The Street - Wed Nov 05, 9:29AM CST
Trade-Ideas LLC identified Endo International (ENDP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ENDP: 66.71 (+0.45)
Endo updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:18AM CST
ENDP: 66.71 (+0.45)
Endo International (ENDP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:55AM CST
ENDP: 66.71 (+0.45)
Endo beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:09AM CST
ENDP: 66.71 (+0.45)
Endo Reports Third Quarter Financial Results
PR Newswire - Wed Nov 05, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported third quarter 2014 revenues of $764 million, an increase of 16 percent compared to third quarter 2013 revenues of $661 million. Endo reported a net loss of $252 million in the third quarter 2014 compared to net income of $40 million in the third quarter of 2013.
ENDP: 66.71 (+0.45), ENL.TO: 74.77 (-0.38)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST
MDLZ: 38.20 (+0.04), CSTE: 59.51 (+0.14), FSS: 15.67 (+0.02), HL: 2.46 (-0.06), BBEP: 15.12 (-0.43), RRD: 16.90 (-0.03), CNP: 24.16 (+0.12), INXN: 28.26 (-0.02), OGE: 36.53 (+0.18), MNTA: 10.63 (unch), GLDD: 7.05 (-0.18), AXAS: 3.89 (-0.18), MEMP: 16.13 (-0.24), PWE: 4.16 (-0.06), ROC: 79.15 (-0.04), SSYS: 104.67 (-0.18), DNR: 9.93 (-1.27), MVIS: 1.70 (unch), PWR: 33.09 (-0.07), COV: 94.39 (+0.41), SMG: 59.94 (-0.66), SEP: 56.90 (+0.54), CLH: 49.80 (+0.85), ATHM: 42.88 (-1.70), STWD: 23.46 (-0.06), BPI: 10.96 (-0.30), LVLT: 48.73 (-0.31), AVA: 33.70 (+0.24), MGA: 104.19 (+0.27), BSFT: 27.42 (-0.08), EE: 37.89 (+0.34), CTSH: 53.03 (-0.25), DAVE: 25.69 (-0.06), NRG: 31.22 (-0.09), CEQP: 8.37 (-0.09), ACT: 249.80 (+6.03), AWR: 34.52 (+0.28), DUK: 80.05 (+0.94), LAMR: 52.77 (+0.22), CCC: 21.06 (-0.16), HFC: 43.18 (+0.35), RTI: 23.45 (-0.17), CHK: 23.03 (-0.18), NUS: 39.26 (-0.14), NICE: 46.40 (-0.02), HRC: 45.04 (+0.28), ENDP: 66.71 (+0.45), SE: 38.44 (+0.32), CBB: 3.41 (-0.06), GTN: 10.20 (+0.09), ANSS: 79.94 (+0.15), RLGY: 42.73 (-0.24), ENB: 45.26 (-0.11), SBGI: 27.96 (-0.13), ARIA: 6.05 (-0.10), LPX: 14.61 (unch), RDC: 23.43 (-0.32), KELYA: 15.12 (-0.30)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 43.88 (+0.74), ENDP: 66.71 (+0.45), VRX: 134.94 (+0.73), PFE: 30.01 (-0.33)
Endo reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:03PM CDT
ENDP: 66.71 (+0.45)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.71 (+0.45), VRX: 134.94 (+0.73), ACT: 249.80 (+6.03), AMGN: 158.68 (+1.00), TKMR: 17.09 (+0.68), GSK: 45.84 (+0.10), AGN: 210.48 (+11.83), JNJ: 108.31 (+0.15), SHPG: 204.81 (+2.19), MRK: 59.62 (+0.55), INFI: 14.25 (+0.15), ABBV: 65.29 (+1.29), KPTI: 40.49 (+0.72)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 66.71 (+0.45), PRGO: 154.09 (-0.37), AUXL: 32.24 (+0.07), DEPO: 15.23 (+0.23), AMPE: 3.32 (-0.02)
(0)
(0)Endo International plc (ENDPQ) Stock Research Links
Scroll down for more posts ▼